Login
Companies $OCUL
$6.01 +$0.00 (0.0%) After hours
OCULAR THERAPEUTIX, INC logo

OCULAR THERAPEUTIX, INC

ocutx.com

What Do They Do?

Develops hydrogel-based eye medicines, including DEXTENZA for surgical eye inflammation and pain and investigational AXPAXLI for retinal diseases, for patients treated by eye-care providers.

How Do They Make Money?

Sells DEXTENZA to specialty distributors and directly to some surgery centers and physicians’ offices; payment for product sales is tied to delivery to the customer.

revenue
SegmentShareRevenue
Product revenue, net
Sold outright

100%
FY2022: 98%
Collaboration revenue
0.3%
FY2022: 2.0%

Who Are Their Customers?

Sells DEXTENZA through specialty distributors to surgery centers, hospital outpatient departments and physicians’ offices, and directly to some surgery centers and physicians’ offices.

Do Revenues Turn Into Profits?

No. It lost $265.9M in FY2025.

Operating income, FY2025
−520% of revenue
▼ −57% (Loss) vs FY2024 (−$171.8M, −270%)
Net income, FY2025
−512% of revenue
▼ −37% (Loss) vs FY2024 (−$193.5M, −304%)
Free cash flow, FY2025
−417% of revenue
▼ −60% (Loss) vs FY2024 (−$136M, −213%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −11%
vs $14.5M in Q3 FY2025
Net income
▼ −37% (Loss)
vs −$69.4M in Q3 FY2025
Product revenue, net share of revenue vs 100.0% in Q3 FY2025

Growing. Revenue grew 19% in 4 years, from $43.5M in FY2021 to $52M in FY2025, about 5% a year.

More focused development pipeline The older report described several development programs for dry eye disease, dry AMD and gene delivery alongside retinal and glaucoma candidates. The latest report centers its clinical pipeline on AXPAXLI for retinal disease and describes OTX-TIC as a program with next steps under evaluation.

Revenue over time
Product revenue, net Collaboration revenue
$100M$50M$0

Who Do They Compete With?

Competes with Regeneron, Genentech, Eyepoint Pharmaceuticals, Kodiak Sciences, 4D Molecular Therapeutics, Adverum Biotechnologies, Eli Lilly and, RegenxBio, Alcon, Glaukos, Roche, Merck, Opus Genetics, AbbVie, PolyActiva, Spyglass Pharma, Icon Biosciences, pSvidia, and Rayner Surgical Group

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support